Company Description
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States.
It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.
The company’s lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection.
It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat Opioid use disorder.Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.
| Country | United States |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | D. Kirkpatrick |
Contact Details
Address: 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 United States | |
| Phone | 858 263 4196 |
| Website | ensysce.com |
Stock Details
| Ticker Symbol | ENSC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001716947 |
| CUSIP Number | 293602108 |
| ISIN Number | US2936024056 |
| Employer ID | 82-2755287 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. D. Lynn Kirkpatrick Ph.D. | President, Chief Executive Officer and Director |
| David C. Humphrey CPA | Chief Financial Officer, Secretary and Treasurer |
| Geoffrey Birkett | Chief Commercial Officer |
| Dr. Jeffrey Millard Ph.d. | Chief Operating Officer |
| Dr. William K. Schmidt Ph.D. | Chairman of Clinical Advisory Board and Chief Medical Officer |
| Dr. Linda Pestano Ph.D. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2025 | D | Notice of Exempt Offering of Securities |
| Apr 24, 2025 | EFFECT | Notice of Effectiveness |
| Apr 24, 2025 | 8-K | Current Report |
| Apr 23, 2025 | EFFECT | Notice of Effectiveness |
| Apr 16, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 16, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 14, 2025 | D | Notice of Exempt Offering of Securities |
| Apr 3, 2025 | SCHEDULE 13G/A | Filing |
| Apr 1, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 8-K | Current Report |